This study is designed to validate the safety (rate of dose limiting adverse effects and treatment failure) of the experimental therapy (trimetrexate/leucovorin plus dapsone) and to determine pharmacokinetics of trimetrexate, leucovorin, and dapsone and trimethoprim in patients with moderately severe Pneumocystis carinii pneumonia.
Showing the most recent 10 out of 553 publications